How FDA's New PMTA Enforcement Policy Affects Vapes & Pouches

The U.S. Food and Drug Administration (FDA) has released a pivotal regulatory document, Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization. This updated guidance defines how the agency will police unauthorized electronic nicotine delivery systems (ENDS) and oral nicotine pouches. By officially withdrawing its April 2020 guidance, the FDA is shifting its resource allocation to address updated youth-use data and the ongoing backlog of pending applications.

Under Section 910 of the Federal Food, Drug, and Cosmetic Act (FDCA), manufacturers must obtain premarket authorization demonstrating that their products are “appropriate for the protection of the public health” (APPH). Because thousands of products remain in regulatory limbo due to FDA review backlogs, this new guidance establishes clear boundaries for which unauthorized products will be tolerated—and which will face immediate regulatory action.

Scope of the New FDA Guidance

The policy applies strictly to two categories of tobacco products containing nicotine from any source:

ENDS: E-cigarettes, vape pens, e-hookahs, personal vaporizers, and cigalikes.
Oral Nicotine Pouches: Pouch products placed between the cheek and gum containing tobacco-derived or synthetic nicotine, excluding loose leaf or ground tobacco.

Deprioritized vs. Prioritized Products

To help manufacturers navigate this transition, the FDA has divided unauthorized products into two distinct enforcement categories based on their PMTA status and design features.

Deprioritized Enforcement (Lower Priority)	Immediate Enforcement (High Priority)
Condition 1: Accepted & Filed PMTA The product must be subject to a pending PMTA accepted for review, or a supplemental PMTA (sPMTA) pending for over 180 days.	Youth-Appealing Features Products depicting cartoons, resembling toys, school supplies, cell phones, or gaming platforms.
Condition 2: Sufficient APPH Data For non-tobacco-flavored ENDS, the pending application must contain sufficient scientific data for the FDA to evaluate its public health impact.	Public Health & Safety Risks Products with exceptionally high nicotine content, lack of child-resistant packaging, fire hazards, or high rates of adverse health events.

The FDA recently demonstrated its strict stance on youth-appealing products by issuing warning letters to retailers selling unauthorized nicotine pouches designed to look like candy, cough drops, and breath strips.

Action Plan for ENDS and Nicotine Pouch Manufacturers

For manufacturers—especially non-U.S. companies based in China and other manufacturing hubs—navigating these rules is critical to maintaining U.S. market access. Companies should immediately take the following steps:

Assess PMTA Eligibility: Verify that your pending applications have achieved “accepted and filed” status with the FDA. Refused applications do not qualify for deprioritization.
Conduct a Gap Analysis: Review pending submissions to ensure they address common deficiencies identified by the FDA, particularly regarding APPH data for flavored products.
Audit Product Designs: Inspect packaging, labeling, and marketing materials to eliminate any features that could be construed as appealing to minors or mimicking everyday household items.
Request Inclusion on the Public List: Manufacturers with applications undergoing active scientific review should contact their FDA Regulatory Health Project Manager (RHPM) to request placement on the FDA’s upcoming public-facing registry of deprioritized products.
Monitor Local State Laws: Federal deprioritization does not shield products from state-level bans or registry laws. Manufacturers must continue to monitor local state-level restrictions.

Author
Recent Posts

Matthew Ma

Marketing at Ecigator

With over a decade of experience in the e-cigarette industry, Matthew Ma is a seasoned expert in both the manufacturing and usage aspects of vaping products. His extensive background has provided him with a deep understanding of the intricacies and evolving dynamics of e-cigarettes.